MN-LHS alumna and CTSI scholar Carolyn Bramante, MD, MPH, led the nation’s first study on whether metformin, fluvoxamine, and ivermectin, or their combinations could serve as possible treatments to prevent ER visits or hospitalization, as well as Long-COVID.
The New England Journal of Medicine published the results of the clinical trial.
“Our trial suggests that metformin may reduce the likelihood of needing to go to the emergency room or be hospitalized for COVID-19,” said Dr. Bramante, an Assistant Professor in the Departments of Internal Medicine and Pediatrics at the University of Minnesota Medical School, in a University news release.
The randomized double-blinded placebo-controlled trial found that the widely available diabetes drug lowered the odds of emergency department visits, hospitalizations, or death due to COVID-19 by over 40 percent; and over 50 percent if prescribed early in onset of symptoms.
